vVardis Secures $175 Million Funding Round Before NYSE Debut
Swiss oral-care startup vVardis has raised $175 million ahead of a planned listing on the New York Stock Exchange.
vVardis, a Swiss oral-care company, has secured $175 million in fresh capital as it prepares to make its debut on the New York Stock Exchange, according to a pre-market advisory issued directly from the NYSE trading floor on Nov. 13, 2026.
The funding round marks a significant milestone for the company as it moves toward a public listing, a process that typically involves heightened investor scrutiny and regulatory disclosure requirements. The capital raise signals that institutional backers are prepared to support vVardis through the transition from private to public markets.
Read more Stark Future Raises €150M+ as Electric Enduro Bikes Lead Market →
The NYSE issues daily pre-market updates from its trading floor, providing market participants with early intelligence on notable corporate events, listings, and broader market conditions before the opening bell. vVardis's fundraising announcement was highlighted as part of that advisory, underscoring its relevance to investors tracking upcoming IPO activity.
While specific details regarding the IPO timeline, share pricing, or the identity of underwriters were not disclosed in the advisory, the size of the raise positions vVardis among the more substantial pre-IPO funding rounds in the consumer health space in recent memory. Analysts tracking the IPO pipeline will likely watch the company's NYSE listing preparations closely in the weeks ahead.
Continue reading at Economic News, Trends, Analysis.